Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025
Akero Therapeutics (NASDAQ: AKRO) presented new analyses of their Phase 2b HARMONY...
Therapeutics
SpringWorks Therapeutics Announces New England Journal of Medicine Publication of Phase 3 DeFi … | National
– Nirogacestat Treatment Significantly Improved Progression-Free Survival, Objective Response Rate and Key Patient Reported Outcomes – – New Drug Application...
SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Nirogacestat for the Treatment of Adults with Desmoid Tumors
SpringWorks Therapeutics, Inc.STAMFORD, Conn., Dec. 27, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused...
Targeting the Notch pathway with gamma secretase inhibitor improves outcomes in patients with rare cancers
Significant improvement in progression-free survival and response rate combined with reduced symptoms and better quality of life are reported as...
SpringWorks Therapeutics Inc. (SWTX) Reports Presentation of Phase 3 DeFi Data at the European Society for Medical Oncology (ESMO) Congress 2022
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here. SpringWorks Therapeutics,...
SpringWorks Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights
Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors Met Its Primary and All Key...
SpringWorks Therapeutics Reports First Quarter 2022
– Activities to Enable the Topline Analysis from Phase 3 DeFi Trial Underway with Data Expected in the Second Quarter...